[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Joincare Pharmaceutical Group Industry Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100620394","phase-3-phase-iii-clinical-study-evaluating-the-safety-pharmacokinetics-and-efficacy-of-jkn2301-dry-suspension-in-pediatric-patients-aged-2-to-under-12-years-with-influenza-100620394",false,"NCT07357051","Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","Inclusion Criteria:\n\n* Pediatric patients within the specified age range.\n* Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test.\n* Presentation for treatment within the early symptomatic phase of influenza illness.\n* Presence of fever and at least one respiratory symptom.\n* Ability to swallow oral suspension.\n* Parent\u002Fguardian and patient (as age-appropriate) able to provide informed consent\u002Fassent.\n\nExclusion Criteria:\n\n* Clinical signs suggestive of severe or complicated influenza infection\n* requiring inpatient management.\n* Presence of a concurrent bacterial infection requiring systemic therapy.\n* Significant immunocompromised, or severe\u002Funcontrolled comorbid conditions.\n* History of hypersensitivity to any component of the investigational products.\n* Use of prohibited medications (including other anti-influenza antivirals) within a specified period prior to enrollment.\n* Recent participation in another interventional clinical trial.\n* Any condition that, in the opinion of the investigator, would jeopardize patient safety or compliance with the study protocol.","ALL","2 Years","11 Years",{"count":20,"type":21},177,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.",[27],"Respiratory Viral Infection","RECRUITING","2026-01-15",{"date":31,"type":32},"2026-01-21","ACTUAL",{"date":34,"type":32},"2025-11-07",{"date":36,"type":21},"2026-04-15",{"name":38,"class":39},"Joincare Pharmaceutical Group Industry Co., Ltd","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":46,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100618337","phase-3-a-phase-3-trial-of-jkn2401-injection-in-copd-100618337","NCT07330310","A Phase 3 Trial of JKN2401 Injection in COPD","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Written informed consent; able and willing to comply with study procedures.\n* Adults with documented COPD diagnosis and medical history consistent with guideline criteria.\n* Relevant exposure history consistent with COPD (e.g., smoking and\u002For biomass exposure).\n* On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.\n* Protocol-defined exacerbation history, symptom burden, and lung function at screening.\n\nExclusion Criteria:\n\n* Current or past asthma, or other clinically significant respiratory disease that may confound assessment.\n* Clinically significant uncontrolled comorbidities that increase risk or interfere with participation\u002Foutcomes.\n* Immunodeficiency\u002Fimmune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history.\n* Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation.\n* Current\u002Frecent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.\n* Prohibited recent vaccines or therapies, prior relevant biologic\u002Ftargeted therapy exposure, severe hypersensitivity to biologics\u002FIMP, pregnancy\u002Fbreastfeeding, or inability to comply (including substance abuse), per investigator judgment.","40 Years","80 Years",{"count":51,"type":21},888,[24],[54],"Chronic Obstructive Pulmonary Disease (COPD)",[56],"JKN2401","NOT_YET_RECRUITING","2026-01-12",{"date":60,"type":32},"2026-01-14",{"date":62,"type":21},"2026-03",{"date":64,"type":21},"2027-11",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100619985","phase-2-a-phase-iia-randomized-double-blind-placebo-controlled-trial-of-jkn2403-in-copd-100619985","NCT07351734","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of JKN2403 Tablets in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)","COPD","Inclusion Criteria:\n\n* Written informed consent; able and willing to comply with study procedures.\n* Adults with documented COPD diagnosis and medical history consistent with guideline criteria.\n* Relevant exposure history consistent with COPD (e.g., smoking).\n* On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.\n* Protocol-defined exacerbation history, symptom burden, and lung function at screening.\n\nExclusion Criteria:\n\n* Current or past asthma, or other clinically significant respiratory disease that may confound assessment.\n* Clinically significant uncontrolled comorbidities that increase risk or interfere with participation\u002Foutcomes.\n* Immunodeficiency\u002Fimmune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history.\n* Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation.\n* Current\u002Frecent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.\n* Prohibited recent vaccines or therapies, prior relevant biologic\u002Ftargeted therapy exposure, severe hypersensitivity to biologics\u002FIMP, - pregnancy\u002Fbreastfeeding, or inability to comply (including substance abuse), per investigator judgment.",{"count":75,"type":21},120,[77],"PHASE2","The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403. The main questions it aims to answer are:\n\nDoes drug JKN2403 reduce the incidence of AECOPD or improve the quality of life or alleviate symptoms related to COPD?\n\nResearchers will compare drug JKN2403 to a placebo (a look-alike substance that contains no drug) to see if drug JKN2403 works to treat moderate-to-severe COPD.\n\nParticipants will:\n\nTake drug JKN2403 or a placebo every day for 24 weeks Visit the clinic once every four weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler",[80],"COPD (Chronic Obstructive Pulmonary Disease)","2026-01-10",{"date":83,"type":32},"2026-01-20",{"date":85,"type":32},"2025-11-06",{"date":87,"type":21},"2026-09-30",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},"100608879","phase-1-phase-i-study-of-singlemultiple-ascending-doses-of-jkn2501-for-injection-in-chinese-healthy-volunteers-100608879","NCT07207291","Phase I Study of Single\u002FMultiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","Inclusion Criteria:\n\n* Voluntary informed consent; able to comply with study requirements and communicate effectively.\n* Healthy subjects aged 18-45 years (inclusive) at screening.\n* BMI 19.0-26.0 kg\u002Fm² (inclusive); weight ≥50 kg (male) or ≥45 kg (female).\n* Vital signs, physical examination, ECG, laboratory tests, chest X-ray, and abdominal ultrasound results judged as normal or clinically insignificant by the investigator.\n* Agreement to use effective non-pharmaceutical contraception from signing ICF until 90 days after last dose; no sperm\u002Fegg donation plans during this period.\n\nExclusion Criteria:\n\n* Pregnant\u002Flactating women; positive pregnancy test; unprotected sex within 2 weeks prior to dosing.\n* Investigator-determined history or presence of clinically significant disorder that may affect safety or trial participation.\n* Use of drugs known to inhibit\u002Finduce hepatic metabolism within 4 weeks, or any medication (prescription, OTC, herbal, vitamins) within 2 weeks prior to dosing; planned use during the trial.\n* Major surgery within 3 months prior to screening or planned during trial; history of surgery potentially affecting results.\n* History of febrile illness or active infection within 2 weeks prior to screening.\n* Blood loss\u002Fdonation \\>400 mL within 3 months prior to screening, or received blood products; plans to donate blood during trial or within 30 days after last dose.\n* History of significant food\u002Fdrug allergy, or allergy to JKN2501\u002Fexcipients.\n* Excessive alcohol consumption; inability to abstain from alcohol from 48h pre-dose until end of study.\n* Smoking ≥5 cigarettes\u002Fday within 3 months prior to screening; inability to abstain from smoking from 48h pre-dose until end of study.\n* History of drug abuse; positive urine drug screen at baseline (Day -1).\n* Positive alcohol breath test at baseline (Day -1).\n* Participation in another interventional clinical trial within 3 months prior to screening or planned during this trial.\n* Estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin.\n* Serum total calcium below lower limit of normal at screening.\n* Investigator-determined unsuitable venous access for PK sampling\u002Finfusion, or history of adverse symptoms\u002Fphobias related to infusion\u002Fphlebotomy.\n* Excessive daily intake of tea, coffee, or caffeinated beverages within 3 months prior to screening.\n* Consumption of grapefruit, Seville oranges, caffeine, or xanthine-rich foods\u002Fbeverages within 48h prior to first dose; inability to abstain during the trial.\n* History of QTc prolongation; or investigator-determined clinically significant ECG abnormalities at screening\u002Fbaseline.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation.",true,"18 Years","45 Years",{"count":100,"type":21},66,[102],"PHASE1","This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts:\n\nPart 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of single ascending intravenous doses of JKN2501 in healthy adults. Biological samples (blood, urine, feces) will be collected for PK analysis.\n\nPart 2 (MAD): Evaluates the safety, tolerability, and PK of multiple ascending intravenous doses of JKN2501 in healthy adults.\n\nDose levels may be adjusted based on emerging safety, tolerability, and PK data from preceding cohorts.",[105,106,107,108],"Bacterial Infections","Urinary Tract Infections","Intra-Abdominal Infections","Respiratory Tract Infections",[105],"2025-09-28",{"date":112,"type":32},"2025-10-03",{"date":114,"type":32},"2025-08-22",{"date":116,"type":21},"2026-03-19",{"name":38,"class":39},""]